Kerry S Courneya Selected Research

beta-Aminoethyl Isothiourea (AET)

1/2016	Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial.
1/2013	Patient satisfaction with participation in a randomized exercise trial: effects of randomization and a usual care posttrial exercise program.
6/2012	A randomized trial of aerobic exercise and sleep quality in lymphoma patients receiving chemotherapy or no treatments.
11/2010	Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy.
9/2009	Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients.
10/2008	Understanding breast cancer patients' preference for two types of exercise training during chemotherapy in an unblinded randomized controlled trial.
4/2008	Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial.
12/2007	Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kerry S Courneya Research Topics

Disease

83	Breast Neoplasms (Breast Cancer) 11/2022 - 04/2002
72	Neoplasms (Cancer) 01/2022 - 01/2002
32	Fatigue 01/2022 - 05/2003
11	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 04/2002
11	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 05/2005
8	Insulin Resistance 01/2022 - 08/2003
8	Obesity 01/2022 - 09/2010
7	Inflammation (Inflammations) 01/2022 - 04/2009
6	Overweight 05/2022 - 08/2010
6	Rectal Neoplasms (Rectal Cancer) 11/2021 - 01/2016
6	Pain (Aches) 01/2018 - 07/2010
5	Hypertension (High Blood Pressure) 01/2020 - 11/2011
4	Colorectal Neoplasms (Colorectal Cancer) 02/2020 - 08/2008
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 06/2004
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 11/2011
4	Anemia 01/2016 - 05/2005
4	Lymphoma (Lymphomas) 01/2013 - 09/2009
3	Urinary Bladder Neoplasms (Bladder Cancer) 05/2022 - 05/2007
3	Colonic Neoplasms (Colon Cancer) 01/2018 - 09/2014
3	Chronic Disease (Chronic Diseases) 01/2016 - 11/2012
3	Type 2 Diabetes Mellitus (MODY) 05/2011 - 12/2008
2	Hypoxia (Hypoxemia) 10/2021 - 01/2019
2	Weight Loss (Weight Reduction) 01/2021 - 01/2017
2	Infections 01/2018 - 07/2013
2	Brain Neoplasms (Brain Tumor) 01/2016 - 07/2015
2	Lung Neoplasms (Lung Cancer) 01/2016 - 03/2009
2	Lymphedema (Milroy Disease) 11/2012 - 10/2007
2	Ovarian Neoplasms (Ovarian Cancer) 08/2011 - 07/2007
1	Death (Near-Death Experience) 11/2021
1	Neoplasm Metastasis (Metastasis) 10/2021
1	Pathologic Complete Response 01/2021
1	Non-Muscle Invasive Bladder Neoplasms 01/2021
1	Kidney Neoplasms (Kidney Cancer) 07/2020
1	Flatulence 02/2020
1	Stroke (Strokes) 02/2019

Drug/Important Bio-Agent (IBA)

26	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2003
11	Insulin (Novolin)FDA Link 01/2021 - 08/2003
9	Estrogens (Estrogen)FDA Link 12/2018 - 04/2005
8	Biological ProductsIBA 10/2021 - 06/2011
8	beta-Aminoethyl Isothiourea (AET)IBA 01/2016 - 12/2007
6	AndrogensIBA 02/2019 - 05/2003
5	Hormones (Hormone)IBA 01/2022 - 05/2003
5	CytokinesIBA 01/2019 - 07/2013
4	Sex Hormone-Binding GlobulinIBA 01/2021 - 03/2010
4	Estradiol (Delestrogen)FDA LinkGeneric 01/2021 - 03/2010
4	Estrone FDA Link 01/2021 - 03/2010
4	Gonadal Steroid Hormones (Sex Hormones)IBA 02/2020 - 03/2010
4	Testosterone (Sustanon)FDA Link 02/2020 - 01/2009
4	AdiponectinIBA 01/2018 - 06/2011
4	C-Reactive ProteinIBA 09/2017 - 09/2005
3	AmberIBA 03/2022 - 11/2012
3	AnthracyclinesIBA 01/2019 - 05/2007
3	Insulin-Like Growth Factor I (IGF-1)IBA 01/2018 - 08/2003
3	LeptinIBA 01/2018 - 06/2011
3	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 08/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2015 - 07/2013
3	Hemoglobins (Hemoglobin)IBA 11/2010 - 09/2008
2	Prostate-Specific Antigen (Semenogelase)IBA 10/2021 - 01/2009
2	Androstenedione (4 Androstene 3,17 dione)IBA 02/2020 - 03/2010
2	Blood Glucose (Blood Sugar)IBA 01/2020 - 11/2011
2	Triglycerides (Triacylglycerol)IBA 01/2020 - 11/2011
2	HDL CholesterolIBA 01/2020 - 11/2011
2	CholesterolIBA 01/2018 - 01/2013
2	Trastuzumab (Herceptin)FDA Link 01/2018 - 05/2007
2	DNA (Deoxyribonucleic Acid)IBA 12/2017 - 01/2016
2	AdipokinesIBA 01/2017 - 06/2011
2	Estrogen ReceptorsIBA 10/2016 - 09/2014
2	LipidsIBA 01/2016 - 01/2009
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 03/2012
2	Interleukin-10 (Interleukin 10)IBA 01/2016 - 06/2014
2	taxaneIBA 09/2014 - 05/2007
2	Interleukin-6 (Interleukin 6)IBA 06/2014 - 07/2013
2	Tumor Biomarkers (Tumor Markers)IBA 06/2012 - 11/2003
2	Insulin-Like PeptidesIBA 09/2010 - 08/2003
1	CarbohydratesIBA 10/2021
1	lipoprotein cholesterolIBA 05/2019
1	LDL CholesterolIBA 05/2019

Therapy/Procedure

50	Therapeutics 10/2021 - 01/2002
28	Drug Therapy (Chemotherapy) 10/2021 - 05/2003
15	Aftercare (After-Treatment) 10/2021 - 08/2002
15	Adjuvant Chemotherapy 07/2021 - 09/2005
11	Resistance Training 07/2021 - 03/2008
11	Radiotherapy 10/2019 - 05/2003
6	Neoadjuvant Therapy 11/2021 - 01/2016
5	Behavior Control 11/2022 - 04/2002
4	Palliative Care (Palliative Therapy) 01/2013 - 11/2009
3	Caloric Restriction 10/2021 - 01/2018
3	Neck Dissection (Radical Neck Dissection) 01/2020 - 06/2004
2	Continuity of Patient Care 11/2021 - 01/2018
2	Activities of Daily Living (ADL) 10/2019 - 05/2003
2	Fitness Trackers 01/2019 - 01/2019
2	Hormone Replacement Therapy (Therapy, Hormone Replacement) 11/2013 - 04/2005
2	Cardiac Rehabilitation 11/2006 - 08/2006
1	Cystectomy 05/2022
1	Tai Ji (Tai Chi Chuan) 11/2021
1	Ketogenic Diet 10/2021
1	Immunotherapy 01/2021
1	Length of Stay 02/2020
1	Colectomy 02/2020
1	Operative Surgical Procedures 10/2019